Innovation for a Common Goal

Mercurio Diabetes mission is to save the lives & limbs of diabetic patients in North America and reduce medical costs by billions of dollars.

Contact Us

Problem Solvers

Mercurio’s goal is to dramatically reduce the over 85,000 yearly amputations in the US due to advanced diabetic foot ulcers

Forward Thinking

Mercurio Biotec Diabetes works closely with the University of Arizona’s Advanced Center for Accelerated Biomedical Innovation (ACABI) headed by Dr. Marvin J. Slepian and Cuba’s Center for Genetic Engineering and Biotechnology to bring the success of Heberprot-P to the United States.

Saving Limbs Globally

With a patient registry of nearly 300,000 people, Heberprot-P has been used to successfully treat diabetic foot ulcers in 30 countries worldwide.

Working to Reduce Diabetes-Related Amputations

Heberprot-P is an innovative, unique Cuban product containing human recombinant epidermal growth factor (hrEGF) for peri- and intra lesional injection; evidence demonstrates it accelerates healing of deep and complex diabetic foot ulcers in >70% of patients, both ischemic and neuropathic, and significantly reduces diabetes-related amputations, thus increasing survival.

Heberprot-P was developed by the Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, licensed in Cuba in 2006, & subsequently in 29 other countries, enabling the safe and effective treatment of nearly 300,000 patients to date without significant adverse events.
Mercurio Biotec LLC has secured the exclusive rights to achieve the clinical testing, FDA approval and subsequent commercialization of Heberprot-P in the United States of America.


Up to 25% of those with diabetes will develop a foot ulcer.


50% of DFU patients (1.4 million) develop infections leading to chronic wounds.


For people on dialysis receiving an amputation, two year mortality is 74%.

Mercurio in the News

Diabetic Foot Congressional Diabetes Caucus presentation by Dr. David Armstrong

Dr. David Armstong

Critical Diabetic Foot Ulcer Statistics

US Annual Expenditure
  • The US annual expenditure for diabetic foot care is $17-20 billion, comparable to annual costs of breast cancer ($16.5B) and colorectal cancer ($14.1B).
  • Economic costs of diabetic foot care, including amputation care, represent the single largest category of excess medical costs associated with diabetes.
Americans Affected
  • Foot ulcers are common among the 29.3 million Americans with diabetes, affecting ≈6% annually (1.7 million) and affecting ≈25% during their lifetime.
  • Advanced diabetic foot ulcers are the primary cause of ≈84% of non-traumatic major amputations among diabetics.
  • There are ≈85,000 amputations due to advanced diabetic foot ulcers in the US annually, more than 7,000 amputations per month.
Mortality Rates
  • The relative 5-year mortality rate after limb amputation is 68%. When compared with cancer – It is second only to lung cancer at 86%. (Colorectal cancer: 39%, Breast cancer: 23%, Hodgkin’s disease: 18%, Prostate cancer 8%)
  •  For people on dialysis receiving an amputation, 2 year mortality is 74%.
  • People with a history of a diabetic foot ulcer have a 40% greater 10 year mortality than people with diabetes alone.
Excessive Costs
  • Diabetic foot ulcers and associated limb loss lead to excess healthcare costs and have a large negative impact on mobility, psychosocial well-being and quality of life, and a 3-year cumulative mortality rate of 28%.
  • Economic costs of diabetic foot care, including amputation care, represent the single largest category of excess medical costs associated with diabetes.
  • The US annual expenditure for diabetic foot care is ≈$17-20 billion, comparable to annual costs of breast cancer ($16.5 B) & colorectal cancer ($14.1 B). 
We believe that there is no better way to heal relations and wounds of the past with Cuba than for our two countries to work together to heal actual wounds of the people in the US and worldwide.